

Cardiaccs Initiates Clinical Trial on Proprietary Monitoring Technology for Open Heart Surgery

OSLO (25 October 2021) – Cardiaccs, a development stage company, said today it has enrolled its first patient in a pilot clinical study to evaluate the performance of the Cardiaccs Monitoring System™, a proprietary sensor system for direct, continuous monitoring of heart function during and following cardiac surgery.

“Initiation of this study is an important milestone in our efforts to advance a potentially game-changing technology for patients undergoing open heart surgery,” said Erik Fosse, MD, Professor of Surgery, Chief Medical officer and founder of Cardiaccs AS. “We are seeking to prove in our clinical study that using the Cardiaccs Monitoring System, surgeons are able to improve patient outcomes through the prevention and earlier detection of complications before they become critical.”

The clinical study will be conducted at Oslo University Hospital, Rikshospitalet, in Norway and Aarhus University Hospital in Denmark. The results of the study are expected to be used to support CE mark and FDA regulatory approvals.

Cardiovascular related diseases are the leading cause of death and hospitalization worldwide with approximately one million cardiac surgeries performed annually in Europe and North America alone.

Cardiaccs AS (www.cardiaccs.com) was founded in 2009 following years of research by the Intervention Centre at Oslo University Hospital. Cardiaccs provides technology for the continuous and accurate monitoring of cardiac function, thereby helping to prevent and better manage complications during and post cardiac surgery.